Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II Trial
-
- Ryuya Yamanaka
- 1Department of Neurosurgery, Brain Research Institute and
-
- Junpei Homma
- 1Department of Neurosurgery, Brain Research Institute and
-
- Naoki Yajima
- 1Department of Neurosurgery, Brain Research Institute and
-
- Naoto Tsuchiya
- 1Department of Neurosurgery, Brain Research Institute and
-
- Masakazu Sano
- 1Department of Neurosurgery, Brain Research Institute and
-
- Tsutomu Kobayashi
- 1Department of Neurosurgery, Brain Research Institute and
-
- Seiichi Yoshida
- 1Department of Neurosurgery, Brain Research Institute and
-
- Takashi Abe
- 2Department of Hematology, Niigata University School of Medicine, Niigata University, Niigata, Japan
-
- Miwako Narita
- 2Department of Hematology, Niigata University School of Medicine, Niigata University, Niigata, Japan
-
- Masuhiro Takahashi
- 2Department of Hematology, Niigata University School of Medicine, Niigata University, Niigata, Japan
-
- Ryuichi Tanaka
- 1Department of Neurosurgery, Brain Research Institute and
書誌事項
- 公開日
- 2005-06-01
- DOI
-
- 10.1158/1078-0432.ccr-05-0120
- 公開者
- American Association for Cancer Research (AACR)
この論文をさがす
説明
<jats:title>Abstract</jats:title><jats:p>Purpose: To investigate the safety and the immunologic and clinical responses of dendritic cell therapy for patients with recurrent malignant glioma.</jats:p><jats:p>Experimental Design: Twenty-four patients with recurrent malignant glioma (6 grade 3 and 18 grade 4 patients) were evaluated in a phase I/II clinical study of dendritic cell therapy. All patients were resistant to the standard maximum therapy. The patient's peripheral blood dendritic cells were generated with granulocyte macrophage colony-stimulating factor, plus interleukin 4 with or without OK-432, and pulsed with an autologous tumor lysate. Dendritic cells were injected intradermally, or both intratumorally and intradermally every 3 weeks.</jats:p><jats:p>Results: The protocols were well tolerated with only local redness and swelling at the injection site in several cases. Clinical responses were as follows: 1 patient with partial response, 3 patients with minor response, 10 patients with stable disease, and 10 patients with progressive disease. The patients whose dendritic cells were matured with OK-432 had longer survival times than the dendritic cells from patients without OK-432 maturation. The patients with both intratumoral and intradermal administrations had a longer survival time than the patients with intradermal administration only. Increased ELISPOT and delayed-type hypersensitivity responses after vaccination could provide good laboratory markers to predict the clinical outcome of patients receiving dendritic cell vaccination. The overall survival of patients with grade 4 glioma was 480 days, which was significantly better than that in the control group.</jats:p><jats:p>Conclusions: This study showed the safety and clinical response of autologous tumor lysate-pulsed dendritic cell therapy for patients with malignant glioma. Dendritic cell therapy is recommended for further clinical studies in malignant glioma patients.</jats:p>
収録刊行物
-
- Clinical Cancer Research
-
Clinical Cancer Research 11 (11), 4160-4167, 2005-06-01
American Association for Cancer Research (AACR)
